Mae Ann Verdan

Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9-50 years: a randomised, controlled, phase 2, non-inferiority study.

M. R. Capeding, G. Dayan, B. Zambrano, 2022, The Lancet. Infectious diseases.

Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.

C. Diazgranados, M. R. Capeding, G. Dayan, 2020, The Lancet. Infectious diseases.